Biopharmaceutical Manufacturing in India, China and
South Korea – Regulatory Framework, Infrastructure Support and Discovery
Funding Create an Environment Conducive to Growth
Summary
GBI Research, the leading business intelligence
provider has released its latest research report, “Biopharmaceutical
Manufacturing in India, China and South Korea – Regulatory Framework,
Infrastructure Support and Discovery Funding Create an Environment Conducive to
Growth”. The report provides an analysis of biopharmaceuticals approved in 2010
and 2011, operating dynamics in the biopharmaceutical industry, the current
scenario in biopharmaceutical manufacturing, key stakeholders, the current
market size (2011) of biopharmaceuticals, and forecasts to 2016 for India,
China, South Korea and the global market. The report also presents trends
witnessed in biopharmaceutical manufacturing, preferred partnership pricing
models, contract manufacturing partnerships, comparative analysis of
biopharmaceutical manufacturing in India, China and South Korea, and the
competitive landscape for the countries covered in the report.
This report is built using data and information
sourced from proprietary databases, primary and secondary research, and
in-house analysis from GBI Research’s team of industry experts.
Leading Contract Manufacturing Organizations (CMOs)
offer manufacturing functions both upstream and downstream equally. In addition
to manufacturing in biopharmaceutical production, they also offer clinical
trials, logistics, packaging, and even marketing. According to industry
experts, almost 60% of the CMO market is dominated by manufacturing functions,
out of which more than 50% is dominated by the downstream process. Many
pharmaceutical companies are expected to outsource most parts of their R&D
and biopharmaceutical manufacturing to emerging economies such as India and
China. Cost rationalization and skilled labor are the main factors facilitating
the outsourcing of processes to these countries. Contract manufacturing is
experiencing an upsurge in these countries; outsourcing activities for
biopharmaceutical manufacturing include secondary manufacturing such as fill
and finish operations, mammalian cell culture, Active Pharmaceutical Ingredient
(API) biologics, microbial fermentation and plant cells. Outsourcing analyses
by pharmaceutical companies reveal that product characterization testing such
as biomanufacturing, toxicity, bioassays and analytical testing form the bulk
of outsourcing to CMOs. With the increase in outsourcing, biomanufacturing
capacities in emerging economies have been expanding. Although the US continues
to be a leader in biopharmaceutical production, with approximately 45% of the
total production share, China’s and India’s shares have been continuously
increasing, with 8% and 7% respectively. Sponsors are building strategic
relationships with the contract players and progressively working towards
homogenizing and simplifying manufacturing processes in order to ensure
normalized products.
Scope
- Detailed overview of biopharmaceutical
manufacturing, the CMO industry, and recent approvals of biopharmaceuticals.
- Annualized market data and forecasts to 2016 for the biopharmaceutical market in India, China and South Korea.
- Detailed overview of key reasons behind outsourcing, outsourcing service models and key drivers and restraints of the market.
- Detailed discussion of trends witnessed in biopharmaceutical manufacturing.
- Company profiles of key biopharmaceutical players in India, China and South Korea, including the key services they offer and the production capacity of the global top 10 biopharmaceutical companies.
- Annualized market data and forecasts to 2016 for the biopharmaceutical market in India, China and South Korea.
- Detailed overview of key reasons behind outsourcing, outsourcing service models and key drivers and restraints of the market.
- Detailed discussion of trends witnessed in biopharmaceutical manufacturing.
- Company profiles of key biopharmaceutical players in India, China and South Korea, including the key services they offer and the production capacity of the global top 10 biopharmaceutical companies.
Reasons
to buy
- Develop market entry and market expansion
strategies by identifying areas for high growth and opportunities.
- Understand the factors shaping the biopharmaceutical industry and trends witnessed in the biopharmaceutical industry.
- Identify the top players in the biopharmaceutical industry, including their financial revenues, geographical presence and key services offered.
- Analyze the key geographies that are lucrative markets for biopharmaceutical production and CMOs.
- Understand upcoming trends that are poised to drive the future growth of biopharmaceutical production.
- Understand the factors shaping the biopharmaceutical industry and trends witnessed in the biopharmaceutical industry.
- Identify the top players in the biopharmaceutical industry, including their financial revenues, geographical presence and key services offered.
- Analyze the key geographies that are lucrative markets for biopharmaceutical production and CMOs.
- Understand upcoming trends that are poised to drive the future growth of biopharmaceutical production.
Buy your copy of this report @ http://www.rnrmarketresearch.com/biopharmaceutical-manufacturing-in-india-china-and-south-korea-regulatory-framework-infrastructure-support-and-discovery-funding-create-an-environment-conducive-to-growth-market-report.html
Report
Details:
Published: Oct 2012
No. of
pages: 82
Price: Single User License: US$ 3500 Corporate User License: US$ 10500
No comments:
Post a Comment